BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheng HR, Kao JH, Wu HL, Tseng TC, Liu CH, Yang HC, Su TH, Chen PJ, Chen DS, Liu CJ. Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection. Hepatol Int 2015;9:35-42. [PMID: 25788377 DOI: 10.1007/s12072-014-9591-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Wen Y, Peng S, Fu L, Fu X, Wu D, Liu B, Tan D, Ouyang Y. Serum levels of miRNA in patients with hepatitis B virus-associated acute-on-chronic liver failure. Hepatobiliary & Pancreatic Diseases International 2018;17:126-32. [DOI: 10.1016/j.hbpd.2018.03.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
2 Nakamura M, Kanda T, Jiang X, Haga Y, Takahashi K, Wu S, Yasui S, Nakamoto S, Yokosuka O. Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis. PLoS One 2017;12:e0177302. [PMID: 28475652 DOI: 10.1371/journal.pone.0177302] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
3 Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to regulatory approval. J Hepatol. 2017;67:847-861. [PMID: 28778687 DOI: 10.1016/j.jhep.2017.05.008] [Cited by in Crossref: 102] [Cited by in F6Publishing: 99] [Article Influence: 20.4] [Reference Citation Analysis]
4 Akuta N, Suzuki F, Kobayashi M, Hosaka T, Fujiyama S, Kawamura Y, Sezaki H, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H. Circulating microRNA-122 levels are important predictor of hepatitis B virus surface antigen seroclearance. J Med Virol 2018;90:1586-92. [PMID: 29896794 DOI: 10.1002/jmv.25238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to regulatory approval. Hepatology. 2017;66:1296-1313. [PMID: 28762522 DOI: 10.1002/hep.29323] [Cited by in Crossref: 129] [Cited by in F6Publishing: 130] [Article Influence: 25.8] [Reference Citation Analysis]
6 Mahmoudian-Sani MR, Asgharzade S, Alghasi A, Saeedi-Boroujeni A, Adnani Sadati SJ, Moradi MT. MicroRNA-122 in patients with hepatitis B and hepatitis B virus-associated hepatocellular carcinoma. J Gastrointest Oncol 2019;10:789-96. [PMID: 31392060 DOI: 10.21037/jgo.2019.02.14] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
7 Bailey WJ, Barnum JE, Erdos Z, LaFranco-Scheuch L, Lane P, Vlasakova K, Sistare FD, Glaab WE. A Performance Evaluation of Liver and Skeletal Muscle-Specific miRNAs in Rat Plasma to Detect Drug-Induced Injury. Toxicol Sci. 2019;168:110-125. [PMID: 30496518 DOI: 10.1093/toxsci/kfy282] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
8 Fu H, Zhang X, Wang Q, Sun Y, Liu L, Huang L, Ding L, Shen M, Zhang L, Duan Y. Simple and rational design of a polymer nano-platform for high performance of HCV related miR-122 reduction in the liver. Biomater Sci 2018;6:2667-80. [PMID: 30209483 DOI: 10.1039/c8bm00639c] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Yen YH, Huang CM, Wei KL, Wang JH, Lu SN, Lee CM, Hung CH, Chen CH, Tseng PL, Chang KC, Tsai MC, Lin MT, Wu CK, Yang CH, Moi SH, Cho CL, Hu TH. MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin. Sci Rep 2016;6:33816. [PMID: 27665934 DOI: 10.1038/srep33816] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
10 Wang WJ, Lai RT, Lu J, Xiang XG, Zhao GD, Tang WL, Cai W, Wang H, Zhou HJ, Xie Q. Correlation between circulating miR-122 and prognosis of chronic HBV-related liver failure. J Dig Dis. 2016;17:334-339. [PMID: 27059663 DOI: 10.1111/1751-2980.12348] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]